Edition:
United Kingdom

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

1.64USD
8:00pm GMT
Change (% chg)

$-0.03 (-1.80%)
Prev Close
$1.67
Open
$1.68
Day's High
$1.68
Day's Low
$1.60
Volume
811,889
Avg. Vol
822,523
52-wk High
$6.99
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Geron Appoints CEO John Scarlett As Chairman, Karin Eastham As Lead Independent Director
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Geron Corp ::GERON ANNOUNCES NEW BOARD LEADERSHIP STRUCTURE.KARIN EASTHAM APPOINTED LEAD INDEPENDENT DIRECTOR.CEO JOHN A. SCARLETT APPOINTED CHAIRMAN.SAYS HOYOUNG HUH RESIGNED FROM THE BOARD.HOYOUNG HUH HAS RESIGNED FROM BOARD, INCLUDING HIS ROLES AS CHAIRMAN OF BOARD.  Full Article

Geron Corp Reports Q3 Revenue $165,000
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Geron Corp ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT COMPANY EVENTS.Q3 LOSS PER SHARE $0.03.Q3 REVENUE $165,000.HAVE CASH TO COMMENCE ENROLLMENT FOR PHASE 3 PORTION OF IMERGE BY MID-YEAR 2019.ENDED Q3 OF 2018 WITH $184.8 MILLION IN CASH AND MARKETABLE SECURITIES.  Full Article

Geron Announces Discontinuation Of Imetelstat Collaboration By Janssen
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Geron Corp ::GERON ANNOUNCES DISCONTINUATION OF IMETELSTAT COLLABORATION BY JANSSEN.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - GERON PLANS TO INITIATE PHASE 3 PORTION OF IMERGE.GERON CORP - REGAINS GLOBAL RIGHTS TO IMETELSTAT PROGRAM.GERON CORP - EFFECTIVE DATE OF TERMINATION IS SEPTEMBER 28, 2018.GERON - TRANSITION OF IMETELSTAT PROGRAM TO GERON IS EXPECTED TO OCCUR OVER APPROXIMATELY 12 MONTHS WITH OPERATIONAL SUPPORT FROM JANSSEN.GERON - JANSSEN IS EXPECTED TO SUPPLY IMETELSTAT TO GERON FOR UP TO 24 MONTHS DURING TRANSITION PERIOD FOR CLINICAL MANUFACTURING.GERON CORP - REVISED ITS FINANCIAL PROJECTIONS AND NOW ANTICIPATES 2018 OPERATING EXPENSES TO BE APPROXIMATELY $37 MILLION.GERON CORP - PLANS TO INITIATE PHASE 3 PORTION OF IMERGE AFTER SPONSORSHIP OF ONGOING IMETELSTAT CLINICAL TRIALS TRANSFERRED FROM JANSSEN TO CO.GERON CORP - ANTICIPATES PATIENT SCREENING AND ENROLLMENT FOR PHASE 3 PORTION OF IMERGE TO BEGIN BY MID-YEAR OF 2019.GERON CORP - HAS ENGAGED A GLOBAL CONTRACT RESEARCH ORGANIZATION (CRO) TO SUPPORT IMETELSTAT CLINICAL DEVELOPMENT.GERON-AS OF AUG 31, HAD ABOUT $183 MILLION IN CASH, MARKETABLE SECURITIES; EXPECTED TO BE SUFFICIENT TO SUPPORT PLANS TO INITIATE PHASE 3 OF IMERGE IN 2019.GERON - EXPECTS FINAL DATA FROM PHASE 2 PORTION OF IMERGE TO BE AVAILABLE IN 2019.  Full Article

Geron Corp Files For Mixed Shelf Offering Of Up To $250 Mln
Thursday, 24 May 2018 

May 24 (Reuters) - Geron Corp ::GERON CORP FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING.  Full Article

Geron Reports Q1 Revenue $318,000
Thursday, 10 May 2018 

May 10 (Reuters) - Geron Corp ::GERON CORPORATION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.04.Q1 REVENUE $318,000.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

US STOCKS-Apple, Amazon set to boost Wall St higher at the open

* Futures up: Dow 0.16 pct, S&P 0.18 pct, Nasdaq 0.38 pct (Adds comment, prices; updates prices)